Meta-analysis of 9 studies (2,564 patients) of MSI-H/dMMR metastatic colorectal cancer on checkpoint inhibitors: response rates did not differ by mutation, but BRAF-mutated tumours had shorter PFS (HR 1.37) and OS (HR 1.74); RAS-mutated had modestly longer PFS (HR 0.81).
Meta-analysisn = 2,564
Pretta et al. Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis